SOURCE: Cardima, Inc.

June 12, 2008 08:45 ET

Atrial Fibrillation Data From UK Study Evaluating the Cardima EP Ablation System

FREMONT, CA--(Marketwire - June 12, 2008) - Cardima, Inc. (OTCBB: CADM) -- Leading Electrophysiology Physicians at Guy's and St. Thomas Hospital, London, UK, have concluded a portion of a study for the treatment of Atrial Fibrillation ("AF"). Guy's and St. Thomas Hospital is a leading cardiac center located in the center of London, England. Patients with both paroxysmal and persistent AF were included in this trial. Cardima's EP Ablation System is being used to treat the patients. To date, Guy's and St. Thomas Hospital has treated over 110 AF patients using the Cardima System.

This UK single center study is on-going, and to date, 30 patients have completed the follow-up monitoring necessary to define success. The principal investigator of the study, Jaswinder Gill MD, FRCP, recently compiled this data on the first 30 patients and presented it at the Fourth Annual Congress of the European Cardiac Arrhythmia Society (ECAS) in Marseille, France on April 13-15th, 2008. His abstract, titled: "Performance of a Novel Linear Catheter Ablating System for Left and Right Atrial Compartmentalization to Reproduce MAZE Operation" has also been accepted for publication by the Journal of Interventional Cardiology and Electrophysiology ("JICE") and is included in Volume 22:1, 2008.

In commenting on his study, Dr. Gill stated: "This early patient data demonstrates that the Cardima EP Ablation System is safe for use in the left atrium. It also illustrates how the Cardima catheter, the REVELATION® T-Flex, can be used to create lesions in the left and right atrium that mimic the Cox Maze for the treatment of AF in a safe and effective manner. Our team looks forward to working with Cardima to expand our study and build a robust body of data that will assist in establishing this linear ablation system as a safe and effective tool for the treatment of AF. Identifying new patient treatment options for AF that are safe and effective is an important public health issue for the UK and many countries around the world."

Cardima's CEO, Robert Cheney, acknowledged the important contribution by Dr. Gill and the team at Guy's and St. Thomas Hospital, "Cardima is very proud to be associated with Guy's and St. Thomas Hospital, a leader in cardiac care, and the highly professional team led by Dr. Gill. The data presented will benefit patients across the UK and the European Union who are in need of AF treatment. We look forward to working with Dr. Gill and his team to expand this study to more centers in the UK over the coming months."

About Cardima

Cardima, Inc. has developed the PATHFINDER®, TRACER® and VUEPORT® Series of diagnostic catheters, the NAVIPORT® Series of guiding catheters, the REVELATION® Series of ablation catheters, the Surgical Ablation System with its series of ablation probes, and the INTELLITEMP® Energy Management Device Series for RF (radiofrequency) energy management. These devices are CE marked and/or received U.S. FDA 510(k) clearance. The REVELATION Series of ablation catheters with the INTELLITEMP EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) with CE mark approval in Europe; it is not yet commercially available in the U.S.

For more information, please visit the Company's website at

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements, including but not limited to building a robust body of data to assist in the establishment of linear ablation systems as a safe and effective tool for the treatment of AF. Potential risks and uncertainties include, but are not limited to: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure FDA approval for the EP ablation applications in the USA and CE mark for the Surgical Ablation probe series with Sheath. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, the Company's Quarterly Report on Form 10-QSB and in the Company's other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.

Contact Information